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ABSTRACT
Background and Objectives: The aim of this study was to identify the association of pregnancy-induced hypertension 
(PIH) or gestational diabetes mellitus (GDM) with the development of venous thromboembolism (VTE). Subjects and 
Methods: This was a retrospective study of 57,009 pregnancies during 2002-2008 at Cheil General Hospital, Kwandong 
University. The diagnosis of VTE {deep vein thrombosis or pulmonary embolism (PE)} was based on clot visualization via 
ultrasound or computed tomography. Results: In total, 27 cases (PE, 20 cases) were detected. The incidence of VTE was 0.47 
per 1,000 pregnancies. To determine risk factors associated with pregnancy-induced VTE, univariate analysis using a chi-square 
test was performed. Cesarean (C)-section, multiple pregnancy, PIH, placenta previa, and assisted reproduction technique (ART) 
were statistically significant compared to the controls (all, p=0.000). However, age, premature rupture of membrane, and GDM 
were not statistically related to VTE. Logistic regression analysis was used to calculate the odds ratios for the risk factors. Pla-
centa previa showed a 12.6-fold higher risk, while PIH had a 9.8-fold higher risk for the occurrence of VTE. C-section and ART 
procedures increased the risk of VTE by 4.2 times compared to that of the controls. Conclusion: Placenta previa and PIH 
were significant risk factors for VTE, whereas the known traditional risk factors of increased age and GDM were not found 
to be associated with VTE. (Korean Circ J 2011;41:23-27)
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Introduction
Venous thromboembolism (VTE) is one of the leading cau-
ses of maternal morbidity and mortality in pregnancy.
1) The 
incidence of VTE is estimated to be 0.76 to 1.72 per 1,000 preg-
nancies, which is four times greater than the risk in the non-
pregnant population.
2) Pregnancy itself induces a prothrom-
botic state with an increase in coagulation factors, a decrease 
in natural anticoagulants such as the coagulation inhibitor 
protein S, and impairment of fibrinolysis, which is probably 
mediated by an increase in plasminogen activator inhibitor.
3) 
These procoagulant changes are important for minimizing 
blood loss during delivery. Pregnancy is also marked by the 
presence of two other components of Virchow’s triad, venous 
stasis and endothelial injury. These homeostatic changes ca-
use an increased risk for VTE.
3)
A hypercoagulable state during pregnancy is known to be 
the most important factor for increasing the risk of VTE. In 
addition to inherited thrombophilia or the antiphospholipid 
syndrome, the assisted reproduction technique (ART), cesa-
rean (C)-section, age older than 35 years, obesity, multiple pr-
egnancies, placenta previa, pregnancy-induced hypertension 
(PIH), and gestational diabetes mellitus (GDM) are also kn-
own risk factors.
1)4-8) Particularly among pregnancy-related 
diseases, PIH and GDM are common during pregnancy, with 
incidences of 6% to 8%, and 2.2% to 8.8%, respectively, and 
are known as VTE risk factors.
9)10) However, recent research 
has questioned the relevance of PIH or diabetes mellitus (DM) 
to VTE.
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the risk factors for the development of VTE in pregnancy, 
and to determine the contributions of PIH and GDM.
Subjects and Methods
Study population
This was a retrospective study of 27 VTE patients out of 
57,009 pregnancies at Cheil General Hospital from January 
2002 to December 2008. Case controls were 56,982 patients 
who did not have VTE during or within four weeks after preg-
nancy, within the same time period.
Diagnostic criteria and data collection
The general characteristics of patients and known risk fac-
tors for VTE, including premature rupture of membrane (PR-
OM), GDM, PIH, C-section, and ART were obtained through 
chart review. The study was approved by the Institutional Re-
view Board of Cheil General Hospital, and authorization for 
the use of data retrieved from medical records for research 
purposes was also obtained. Only patients with manifesta-
tions of proximal deep vein thrombosis (DVT) and pulmo-
nary embolism (PE) were considered to have VTE and were 
studied. The diagnosis of DVT was objectively confirmed by 
an intraluminal filling defect and noncompression viewed by 
color Doppler ultrasonography. PE was confirmed by obser-
vation of an intraluminal filling defect on computed tomog-
raphy pulmonary angiography. 
PIH includes gestational hypertension, preeclampsia/ec-
lampsia, and preeclampsia superimposed on chronic hyper-
tension. To diagnose GDM, a 50 g oral glucose tolerance (OGT) 
test was conducted at 24-28 weeks of pregnancy. When the 
glucose level in a 50 g OGT test was greater than 140 mg/dL, 
a 100 g OGT test was performed. According to the Carpenter-
Coustan criteria,
13) GDM was diagnosed when patient glucose 
levels exceeded two or more of the following thresholds: fast-
ing glucose, 95 mg/dL; one hour glucose, 180 mg/dL; two hour, 
155 mg/dL; or three hour, 140 mg/dL. 
Statistical analysis
Statistical Package for the Social Sciences (SPSS) 12.0 for 
Windows (SPSS, Chicago, IL, USA) was used for statistical 
analysis. Results were expressed as the mean±SD. Risk factors 
for VTE were analyzed using a Chi-square test and linear lo-
gistic regression models, and are presented as risk ratios with 
95% confidence interval (CI). Statistical significance was con-
sidered to be p<0.05. 
Results
There were 27 VTE patients identified out of 57,009 deliv-
eries, for a frequency of 0.47 VTE patients/1,000 deliveries, 
which is similar to the results of other studies. The mean pa-
tient age was 31.8±3.5 years (17-53 years) at the time of de-
livery. In this study, the frequency of PE was 0.035%, higher 
than the 0.012% for DVT. The rate for C-section delivery was 
38.8%, for multiple pregnancies was 2.6%, for GDM was 1.9%, 
for PIH was 1.3%, for placenta previa was 0.6%, and for PR-
OM was 8.9%. ART was used in 4.3% of patients (Table 1).
To identify the risk factors associated with pregnancy-in-
duced VTE, univariate analysis using a Chi-square test was 
Table 1. Baseline characteristics of the study population
Characteristic N (total=57,009) Percent
Cesarean section 22,096 38.8
Multiple pregnancies 1,460 02.6
Gestational diabetes 1,055 01.9
PIH 753 01.3
Placenta previa 332 00.6
PROM 5,089 08.9
ART 2,461 04.3
VTE: venous thromboembolism, PIH: pregnancy-induced hyper-
tension, PROM: premature rupture of the membrane, ART: assisted 
reproduction technology
Table 2. Risk factors for VTE in pregnancy (univariate analysis)
Risk factor
VTE
patients
(n=27, %)
Controls
(n=56,982, %)
p
Age (years)
   <35
   ≥35
17 (63.0)
10 (37.0)
45,250 (79.4)
11,732 (20.6)
0.061
Cesarean section
   Yes
   No
21 (77.8)
06 (22.2)
22,075 (38.7)
34,907 (61.2)
0.000
Multiple pregnancies
   Yes
   No
05 (18.5)
22 (81.5)
1,455 (2.6)
55,527 (97.4)
0.000
Gestational diabetes
   Yes
   No
 
1 (3.7)
26 (96.3)
1,054 (1.8)
55,928 (98.1)
0.475
PIH
   Yes
   No
05 (18.5)
22 (81.5)
0.748 (1.3)
56,234 (98.6)
0.000
Placenta previa
   Yes
   No
03 (11.1)
24 (88.9)
0.329 (0.6)
56,653 (99.4)
0.000
PROM
   Yes
   No
2 (7.4)
25 (92.6)
5,087 (8.9)
51,895 (91)0.
0.782
ART
   Yes
   No
07 (26.0)
20 (74.1)
2,454 (4.3)
54,528 (95.6)
0.000
VTE: venous thromboembolism, PIH: pregnancy-induced hyper-
tension, PROM: premature rupture of the membrane, ART: assisted 
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performed. As variables, PIH and GDM, in addition to tradi-
tional risk factors for VTE, such as age, C-section, multiple 
pregnancy, placenta previa, and ART were included. C-sec-
tion (p=0.000), multiple pregnancy (p=0.000), PIH (p=0.000), 
placenta previa (p=0.000), and ART (p=0.000) were statisti-
cally significant compared to the controls. However, age (p= 
0.061), PROM (p=0.782), and GDM (p=0.475), which are th-
ought to be risk factors for VTE, were not statistically associ-
ated with VTE (Table 2). Using logistic regression analysis, the 
odds ratios of risk factors were calculated. Placenta previa had 
a 12.6-fold higher risk, and PIH had a 9.8-fold higher risk 
for the occurrence of VTE. C-section and ART procedures in-
creased the risk for VTE 4.2-fold compared to the controls. 
Multiple gestations, which showed a close correlation by uni-
variate analysis, demonstrated no significant association (p= 
0.149) (Table 3) (Fig. 1). Age, GDM, and placenta abruptio 
did not increase the risk for VTE during or after pregnancy. 
Discussion
In this study, we found that PIH was closely correlated with 
pregnancy-induced VTE. Another new finding was that pla-
centa previa contributed to the development of VTE, which 
has not been seen in other studies. Moreover, we found that 
there was no association of VTE with patient age or GDM, wh-
ich are usually assumed to be VTE risk factors in pregnancy. 
Because VTE during pregnancy or after delivery may be fa-
tal to both mother and baby, understanding the risk factors 
and providing early thromboprophylaxis can help prevent VTE 
development.
14) More than 50% of VTE occurs in the first 
two trimesters, and use of early thromboprophylaxis has been 
emphasized during pregnancy of patients at high risk for VTE. 
One of the most important risk factors for VTE in pregnancy 
is a history of thrombosis.
11)15-17) In addition to thrombophilia, 
many studies have reported that C-section, PIH, multiparity, 
multiple gestation, GDM, and age (age >35) are risk factors for 
VTE in pregnancy.
7)18)19) In a large Swedish study, C-section in-
creased the risk of postpartum thrombosis by 5-fold,
7) and 
this result was confirmed in another study.
19)
Preeclampsia is known as a significant risk factor for VTE. 
Lindqvist et al.
7) found no association of preeclampsia with 
antepartum VTE, but preeclampsia increased the risk of po-
stpartum VTE by 3-fold. However, Ros et al.
8) reported that 
preeclampsia was associated with both antepartum and post-
partum VTE. In severe preeclampsia, the risk for VTE was 
elevated 4.8-fold. In another study determining the associa-
tion of hypertensive pregnancy with cardiovascular (CV) and 
thromboembolic events, gestational hypertension, mild pre-
eclampsia, and severe preeclampsia increased the risk for VTE 
by 2.8-, 2.2-, and 3.3-fold, respectively.
20) A number of mecha-
nisms may explain the observed association between VTE and 
CV disease. Adverse physiological changes developing dur-
ing preeclampsia, such as endothelial cell dysfunction, he-
modynamic abnormalities, and insulin resistance may con-
tribute to VTE occurrence during and after delivery.
21)22)
In diabetes, high blood glucose promotes vascular inflam-
mation leading to increased risk of a CV event. Regarding st-
udy on the association between diabetes and VTE, a popula-
tion-based case-control study, based on Rochester Epidemio-
logy Project data from 1976 to 2000, showed that DM and 
Table 3. Risk factors for venous thromboembolism in pregnancy (multiple regression analysis)
B SE Wals Sig. Exp (B)
95% CI for EXP (B) 
Lower Upper
Age 0.048 0.055 0.764 0.382 1.050 0.942 1.170
Cesarean section 1.231 0.497 6.146 0.013 3.425 1.294 9.066
Multiple pregnancies 0.823 0.570 2.087 0.149 2.277 0.746 6.954
GDM 0.503 1.031 0.238 0.626 1.653 0.219 12.464
PIH 2.287 0.522 19.216 0.000 9.841 3.540 27.355
Placenta previa 2.534 0.651 15.143 0.000 12.608 3.518 45.185
Placenta abruption 0.080 0.741 0.012 0.914 1.083 0.254 4.624
ART 1.424 0.506 7.924 0.005 4.155 1.541 11.203
Constant -1.548 2.521 0.377 0.539 0.213
GDM: gestational diabetes mellitus, PIH: pregnancy-induced hypertension, ART: assisted reproduction technology
Fig. 1. Odds ratios of risk factors for venous thromboembolism in pr-
egnancy and the puerperium. GDM: gestational diabetes mellitus, 
PIH: pregnancy-induced hypertension, ART: assisted reproduction 
technology.
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diabetes complications are not independent risk factors for 
incident VTE.
12) The theoretical mechanism that leads to the 
development of VTE, is that the atherosclerotic risk factors 
of diabetes, infection and hypercoagulability, affect VTE de-
velopment. Many studies have revealed the association of dia-
betes with VTE and PE,
23)24) and results of a recent meta-an-
alysis that diabetes increased the risk for VTE 1.42-fold (95% 
CI, 1.12-1.77) support the association.
25) A register-based case-
control study in Norway also showed that GDM increased an-
tenatal VTE by 4.0-fold (95% CI, 2.0-8.9).
1) Interestingly, they 
did not find that GDM predicts postnatal VTE, suggesting 
that antepartum and postpartum VTE may involve different de-
velopmental mechanisms. Therefore, large differences exist 
between the unadjusted and adjusted odd ratios for all post-
natal risk factors (preeclampsia, placenta previa, placenta ab-
ruptio, ART, and C-section). In this study, age and multiple 
pregnancies, which have been thought to be risk factors for 
VTE in pregnancy, demonstrated no association with postna-
tal VTE. 
Our study reconfirmed the known risk factors of VTE in 
pregnancy, including the strong relationship between PIH 
and VTE in pregnancy, and found another new risk factor, 
placenta previa. Since in this study, age and GDM were not 
risk factors for VTE in pregnancy, if our results are confirm-
ed, this finding could help reduce unnecessary diagnostic tests 
and the use of thromboprophylaxis. Even though thrombo-
prophylaxis during pregnancy is relatively safe, bleeding, os-
teoporosis, thrombocytopenia, skin necrosis, and other ad-
verse effects frequently continue to occur after anticoagulat-
ion therapy.
26-28) More research is needed to produce better 
guidelines for thromboprophylaxis. 
Our study has many limitations. Most importantly, this st-
udy was performed in one center and had a very small num-
ber of patients. Because the frequency of VTE is so low, it is 
difficult to conduct an association study in a single center; 
therefore, multicenter registry studies are needed. Another 
limitation is that our study did not consider the difference be-
tween antepartum and postpartum VTE. In our study, we had 
only five cases of antepartum VTE, and the remaining 22 
cases developed in the postpartum period. Therefore, our re-
sults are more relevant to postpartum VTE, and more cases 
are needed to clarify VTE differences occurring before and 
after delivery, because ante- and postpartum risk patterns are 
different. Moreover, the diagnosis of DVT during pregnancy 
is generally hard to make. Since dyspnea, tachypnea, swelling, 
and discomfort in the legs are common during pregnancy 
and sometimes go without treatment, the incidence of actual 
DVT seems to be underestimated. This is why the incidence of 
DVT in our study was so low, and more aggressive effort sh-
ould be devoted to the diagnosis of DVT in a larger study.
In conclusion, our study revealed that PIH, but not GDM, 
was associated with VTE in pregnancy. However, a large-sc-
ale, multicenter registry study is still required to determine the 
relationship between GDM and VTE. 
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